Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.

Post time 2024-4-27 19:19:09

journal：Journal of Clinical Oncology

Authors：Yael Bar; Aylin S. Dedeoglu; Geoffrey G. Fell; Natalie J. Moffett; Baris Boyraz; Amy Ly; Aditya Bardia; Beverly Moy; Leif W. Ellisen; Steven J. Isakoff

Published date：2023-6-1

DOI：10.1200/jco.2023.41.16_suppl.1005

PDF link：https://ascopubs.org/doi/pdfdire ... 23.41.16_suppl.1005

Article link：http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1005

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 2024-4-27 19:19:10

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies. Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.